EGFR and non-small cell lung carcinoma: Also, Gefitinib and Erlotinib, two anti-EGFR TKIs, have been correlated with the induction of senescence in EGFR-mutant and non-mutant NSCLC cell lines (Hotta et al., 2007; Wang et al., 2011; Sugita et al., 2015).